Tag:

Eli Lilly

Latest Headlines

Latest Headlines

Industry Voices: How to win at animal health

Animal health, which for decades was little more than a side business for big pharma companies, has emerged as a beacon of growth and an important profit driver in the industry. The rise of animal health as a growth engine has set off a flurry of deal making, attracted an influx of capital and created an increasingly dynamic marketplace for pet and livestock pharmaceuticals.

Sanofi hits Lilly with more Lantus infringement charges

Sanofi has already slapped Eli Lilly with one patent infringement lawsuit over its Lantus copy, effectively keeping the competitor off the market until at least mid-2016. But now, it's filed another, wider suit.

Sanofi ups the legal ante to block Lilly's Lantus biosimilar

Sanofi has filed another lawsuit against Eli Lilly in hopes of beating back a biosimilar challenge for its top-selling insulin product, claiming its rival's in-development knockoff infringes its intellectual property.

Lilly partners with China's Yabao on diabetes drug

Eli Lilly is partnering with Beijing-based Yabao Pharmaceuticals on the development of its early-stage diabetes drug LY2608204.

FierceAnimalHealth: Bringing a unique approach to the animal health industry

It has been a big couple of years for the animal health industry. With  FierceAnimalHealth, we will be keeping tabs on a slew of companies that are new to us and so we urge you to help us get to know you and to keep us apprised of the essential news in the industry. And please pass along your suggestions.

UPDATED: Sanofi's Lantus empire imperiled as EU recommends Lilly, Boehringer biosimilar

Sanofi's Lantus is not only the best-selling diabetes drug in the world; it is one of the best selling drugs in the world with $7.6 billion in 2013 revenues. But the foundation for this juggernaut is starting to crack. The EU Friday recommended approval a biosimilar of Lantus developed by Eli Lilly and Boehringer Ingelheim.

Lilly and Boehringer inch closer to challenging Lantus with EU nod

Eli Lilly and Boehringer Ingelheim have convinced European regulators to recommend their biosimilar of Sanofi's Lantus, the world's top-selling insulin, setting the stage for a near-term approval and launch once the reference product comes off patent next year.

Eli Lilly's anti-takeover superpower? A shield forged by Indiana lawmakers

Eli Lilly & Co. won't be needing pepper spray to fend off unwanted suitors. That's not because it lacks charm or offers few attractive assets, Bernstein analyst Tim Anderson says. A quirk in Indiana law protects the drugmaker from hostile takeovers.

Can clot-fighters get a boost from the U.K.'s new enthusiasm?

The cost-effectiveness watchdogs in the U.K. really, really want people to take their clot-busting drugs. Days ago, the National Institute for Health and Care Excellence touted the benefits of anticoagulants for patients with atrial fibrillation, and now, they're considering new backing for Eli Lilly's Effient.

What's next in diabetes drugs? The pulse of R&D at ADA14

Convening in San Francisco for the annual conference of the American Diabetes Association this weekend, drugmakers angled for the spotlight in a field made up mostly of similar treatments with small differentiations that could spell the difference between blockbuster sales and also-ran status.